文献速递核素与放射性配体治疗肿瘤 PET/CT

体重指数升高与接受前列腺特异性膜抗原导向放射性配体治疗的去势抵抗性前列腺癌患者总生存期改善相关

Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy.
PubMed 文献 · J Nucl Med · 2023-06-08

本研究纳入171例计划接受前列腺特异性膜抗原(PSMA)导向放射性配体治疗(RLT)的患者,分析体重指数(BMI)及CT来源体成分参数对总生存期(OS)的预测价值。结果显示,超重和肥胖患者OS较长,肌肉减少症对OS无显著影响;多变量分析中较高BMI、较低CRP、较低LDH及较长初诊至RLT间隔为OS的显著预测因素。

要点

  • 超重(25≥BMI>30)和肥胖(BMI≥30)患者OS分别为14个月和13个月,均长于正常体重者的8个月。
  • 肌肉减少症对OS无显著影响(11 vs. 12个月;HR 1.4;95% CI 0.91-2.1;P=0.09)。
  • 多变量分析中较高BMI(HR 0.91)、较低CRP(HR 1.09)、较低LDH(HR 1.08)及较长初诊至RLT间隔(HR 0.95)为OS显著预测因素。

核心结论

  • BMI评估的脂肪储备增加、CRP、LDH及初诊至RLT间隔是OS的相关预测因素,而CT来源体成分参数不是。
  • 作者认为,鉴于BMI可被改变,未来研究应探讨在PSMA RLT前或期间采用高热量饮食是否可改善OS。

研究设计与样本

  • 研究纳入171例计划接受PSMA导向RLT的患者,测定BMI(kg/m2)及L3-L4水平CT来源体成分参数(总脂肪面积、皮下脂肪面积、内脏脂肪面积及腰大肌面积)。
  • 经身高标准化后使用腰大肌指数定义肌肉减少症,采用Kaplan-Meier曲线和Cox回归进行结局分析,并用Harrell C指数进行拟合优度分析。

主要发现

  • 65例(38%)患者存在肌肉减少症,98例(57.3%)患者BMI升高。
  • 正常体重(BMI<25)男性OS为8个月,超重(25≥BMI>30)男性OS为14个月(HR 0.63;95% CI 0.40-0.99;P=0.03),肥胖(BMI≥30)男性OS为13个月(HR 0.47;95% CI 0.29-0.77;P=0.004)。
  • 肌肉减少症对OS无显著影响(11 vs. 12个月;HR 1.4;95% CI 0.91-2.1;P=0.09)。
  • 单变量分析中多数体成分参数与OS紧密相关,BMI的C指数最高。
  • 多变量分析中,较高BMI(HR 0.91;95% CI 0.86-0.97;P=0.006)、较低CRP(HR 1.09;95% CI 1.03-1.14;P<0.001)、较低LDH(HR 1.08;95% CI 1.03-1.14;P<0.001)及较长初诊至RLT间隔(HR 0.95;95% CI 0.91-0.99;P=0.02)为OS的显著预测因素。

临床怎么用

  • 作者认为,BMI可被改变,未来研究应探讨在PSMA RLT前或期间采用高热量饮食是否可改善OS。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In patients with prostate cancer scheduled for systemic treatment, being overweight is linked to prolonged overall survival (OS), whereas sarcopenia is associated with shorter OS. We investigated fat-related and body composition parameters in patients undergoing prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) to assess their predictive value for OS. Methods: Body mass index (BMI, in kg/m2) and CT-derived body composition parameters (total, subcutaneous, visceral fat area, and psoas muscle area at the L3-L4 level) were determined for 171 patients scheduled for PSMA-directed RLT. After normalization for stature, the psoas muscle index was used to define sarcopenia. Outcome analysis was performed using Kaplan-Meier curves and Cox regression including fat-related and other clinical parameters (Gleason score, C-reactive protein [CRP], lactate dehydrogenase [LDH], hemoglobin, and prostate-specific antigen levels). The Harrell C-index was used for goodness-of-fit analysis. Results: Sixty-five patients (38%) had sarcopenia, and 98 patients (57.3%) had increased BMI. Relative to the 8-mo OS in normal-weight men (BMI < 25), overweight men (25 ≥ BMI > 30) and obese men (BMI ≥ 30) achieved a longer OS of 14 mo (hazard ratio [HR], 0.63; 95% CI, 0.40-0.99; P = 0.03) and 13 mo (HR, 0.47; 95% CI, 0.29-0.77; P = 0.004), respectively. Sarcopenia showed no impact on OS (11 vs. 12 mo; HR, 1.4; 95% CI, 0.91-2.1; P = 0.09). Most of the body composition parameters were tightly linked to OS on univariable analyses, with the highest C-index for BMI. In multivariable analysis, a higher BMI (HR, 0.91; 95% CI, 0.86-0.97; P = 0.006), lower CRP (HR, 1.09; 95% CI, 1.03-1.14; P < 0.001), lower LDH (HR, 1.08; 95% CI, 1.03-1.14; P < 0.001), and longer interval between initial diagnosis and RLT (HR, 0.95; 95% CI, 0.91-0.99; P = 0.02) were significant predictors of OS. Conclusion: Increased fat reserves assessed by BMI, CRP, LDH, and interval between initial diagnosis and RLT, but not CT-derived body composition parameters, were relevant predictors for OS. As BMI can be altered, future research should investigate whether a high-calorie diet before or during PSMA RLT may improve OS.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hartrampf PE, Mihatsch PW, Seitz AK, et al. Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy. J Nucl Med. 2023. PMID: 37290794. doi:10.2967/jnumed.122.265379

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。